Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs

详细信息    查看全文

• 作者：Nina Lagerqvist (1) (2) (4)
  Jonas N?slund (2) (3)
  ?ke Lundkvist (2) (3)
  Michèle Bouloy (5)
  Clas Ahlm (2)
  G?ran Bucht (1) (6)
  
• 刊名：Virology Journal
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：6
• 期：1
• 全文大小：881KB
• 参考文献：1. Gerdes G: Rift Valley fever. / Rev Sci Tech 2004,23:613-23.
  2. Balkhy H, Memish Z: Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. / Int J Antimicrob Agents 2003,21:153-57. CrossRef
  3. Elliott R: / The Bunyaviridae New York: Plenum Press 1996.
  4. Flick R, Bouloy M: Rift Valley fever virus. / Curr Mol Med 2005,5:827-34. CrossRef
  5. Pittman P, Liu C, Cannon T, Makuch R, Mangiafico J, Gibbs P, Peters C: Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. / Vaccine 1999,18:181-89. CrossRef
  6. Kark J, Aynor Y, Peters C: A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. / Am J Epidemiol 1982,116:808-20.
  7. Smithburn KC: Rift Valley Fever: The neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. / Br J Exp Pathol 1949, 1-6.
  8. Metwally S: Foreign animal diseases. / 7 Edition / (Edited by: Brown C, Torres A). Boca Raton, FL: Boca Publications Group, Inc 2008, 369-76.
  9. Botros B, Omar A, Elian K, Mohamed G, Soliman A, Salib A, Salman D, Saad M, Earhart K: Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. / J Med Virol 2006,78:787-91. mv.20624">CrossRef
  10. Coetzer J, Barnard B: Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents. / Onderstepoort J Vet Res 1977,44:119-26.
  11. Lubroth J, Rweyemamu M, Viljoen G, Diallo A, Dungu B, Amanfu W: Veterinary vaccines and their use in developing countries. / Rev Sci Tech 2007,26:179-01.
  12. Muller R, Saluzzo J, Lopez N, Dreier T, Turell M, Smith J, Bouloy M: Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. / Am J Trop Med Hyg 1995,53:405-11.
  13. Caplen H, Peters C, Bishop D: Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. / J Gen Virol 1985,66:2271-277. CrossRef
  14. Vialat P, Muller R, Vu T, Prehaud C, Bouloy M: Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. / Virus Res 1997,52:43-0. CrossRef
  15. Hunter P, Erasmus B, Vorster J: Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. / Onderstepoort J Vet Res 2002,69:95-8.
  16. Beláková J, Horynová M, Krupka M, Weigl E, Raska M: DNA vaccines: are they still just a powerful tool for the future? / Arch Immunol Ther Exp (Warsz) 2007,55:387-98. CrossRef
  17. Giese M: DNA-antiviral vaccines: new developments and approaches-a review. / Virus Genes 1998,17:219-32. CrossRef
  18. Donnelly J, Wahren B, Liu M: DNA vaccines: progress and challenges. / J Immunol 2005,175:633-39.
  19. Liu M, Wahren B, Karlsson Hedestam G: DNA vaccines: recent developments and future possibilities. / Hum Gene Ther 2006,17:1051-061. m.2006.17.1051">CrossRef
  20. Wallace D, Ellis C, Espach A, Smith S, Greyling R, Viljoen G: Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. / Vaccine 2006,24:7181-189. CrossRef
  21. Schmaljohn C, Parker M, Ennis W, Dalrymple J, Collett M, Suzich J, Schmaljohn A: Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. / Virology 1989,170:184-92. CrossRef
  22. Spik K, Shurtleff A, McElroy A, Guttieri M, Hooper J, SchmalJohn C: Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. / Vaccine 2006,24:4657-666. CrossRef
  23. Wang Q, Wang X, Hu S, Ge J, Bu Z: Study on DNA immune of envelope protein gene of Rift Valley Fever Virus. / Wei Sheng Wu Xue Bao 2007,47:677-81. [abstract, article in Chinese]
  24. Meegan J: The Rift Valley fever epizootic in Egypt 1977-8. 1. Description of the epizzotic and virological studies. / Trans R Soc Trop Med Hyg 1979,73:618-23. CrossRef
  25. Sall A, Zanotto P, Sene O, Zeller H, Digoutte J, Thiongane Y, Bouloy M: Genetic reassortment of Rift Valley fever virus in nature. / J Virol 1999,73:8196-200.
  26. Bird B, Khristova M, Rollin P, Ksiazek T, Nichol S: Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. / J Virol 2007,81:2805-816. CrossRef
  27. Johansson P, Olsson M, Lindgren L, Ahlm C, Elgh F, Holmstr?m A, Bucht G: Complete gene sequence of a human Puumala hantavirus isolate, Puumala Ume?/hu: sequence comparison and characterisation of encoded gene products. / Virus Res 2004,105:147-55. CrossRef
  28. Lindkvist M, Lahti K, Lillieh??k B, Holmstr?m A, Ahlm C, Bucht G: Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins. / Vaccine 2007,25:1690-699. CrossRef
  29. Johansson P, Lindgren T, Lundstr?m M, Holmstr?m A, Elgh F, Bucht G: PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine. / Vaccine 2002,20:3379-388. CrossRef
  30. Aida Y, Pabst M: Removal of endotoxin from protein solutions by phase separation using Triton X-114. / J Immunol Methods 1990,132:191-95. CrossRef
  31. N?slund J, Lagerqvist N, Lundkvist A, Evander M, Ahlm C, Bucht G: Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. / J Virol Methods 2008,151:277-82. met.2008.04.007">CrossRef
  32. Bucht G, Sj?lander K, Eriksson S, Lindgren L: Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. / Vaccine 2001,19:3820-829. CrossRef
  33. G?tt P, Z?ller L, Darai G, Bautz E: A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein. / Virus Genes 1997,14:31-0. CrossRef
  34. Lundkvist A, Meisel H, Koletzki D, Lankinen H, Cifire F, Geldmacher A, Sibold C, G?tt P, Vaheri A, Krüger D, Ulrich R: Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. / Viral Immunol 2002,15:177-92. CrossRef
  35. Kutzler M, Weiner D: DNA vaccines: ready for prime time? / Nat Rev Genet 2008,9:776-88. CrossRef
  36. Gori Savellini G, Di Genova G, Terrosi C, Di Bonito P, Giorgi C, Valentini M, Docquier J, Cusi M: Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. / Virology 2008,375:521-28. CrossRef
  37. Dean H, Haynes J, Schmaljohn C: The role of particle-mediated DNA vaccines in biodefense preparedness. / Adv Drug Deliv Rev 2005,57:1315-342. CrossRef
  38. Dalrymple JMSEH, Kakach LT, Collet MS: Mapping protective determinants of Rift Valley Fever Virus using recombinant vaccinia viruses. / Vaccines 89 1989, 371-75.
  39. Collett MS, Keegan K, Hu SL, Sridhar P, Purchio AF, Ennis WH, Dalrymple JM: Protective subunit immunogens to RVFV from bacteria and recombinant vaccinia virus. / The biology of negative stranded viruses / (Edited by: Mahy B, Kolakofsky D). New York, NY: Elsevier 1987, 321-29.
  40. Besselaar T, Blackburn N: Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies. / Arch Virol 1991,121:111-24. CrossRef
  41. Besselaar T, Blackburn N: The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity. / Res Virol 1994,145:13-9. CrossRef
  42. Lorenzo G, Martín-Folgar R, Rodríguez F, Brun A: Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. / Vaccine 2008,26:5255-262. CrossRef
  43. Liu L, Celma C, Roy P: Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. / Virol J 2008,5:82. CrossRef
  44. Martin J, Pierson T, Hubka S, Rucker S, Gordon I, Enama M, Andrews C, Xu Q, Davis B, Nason M, Fay M, Koup Roederer M, Bailer R, Gomez P, Mascola J, Chang G-J, Nabel G, Graham B: A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. / J Infect Dis 2007,196:1732-740. CrossRef
  
• 作者单位：Nina Lagerqvist (1) (2) (4)
  Jonas N?slund (2) (3)
  ?ke Lundkvist (2) (3)
  Michèle Bouloy (5)
  Clas Ahlm (2)
  G?ran Bucht (1) (6)
  
  1. Department of CBRN Defence and Security, Swedish Defence Research Agency, SE, 901 82, Ume?, Sweden
  2. Department of Clinical Microbiology, Division of Infectious Diseases, Ume? University, SE, 901 85, Ume?, Sweden
  4. Swedish Institute for Infectious Disease Control, SE, 171 82, Solna, Sweden
  3. Department of Clinical Microbiology, Division of Virology, Ume? University, SE, 901 85, Ume?, Sweden
  5. Unité de Génétique Moléculaire des Bunyaviridés, Institut Pasteur, Paris, France
  6. National Environment Agency, Environmental Health Institute, 11 Biopolis Way, 06-05/08, Helios Block, 138667, Singapore
  
• ISSN：1743-422X

文摘

Background Affecting both livestock and humans, Rift Valley Fever is considered as one of the most important viral zoonoses in Africa. However, no licensed vaccines or effective treatments are yet available for human use. Naked DNA vaccines are an interesting approach since the virus is highly infectious and existing attenuated Rift Valley Fever virus vaccine strains display adverse effects in animal trials. In this study, gene-gun immunisations with cDNA encoding structural proteins of the Rift Valley Fever virus were evaluated in mice. The induced immune responses were analysed for the ability to protect mice against virus challenge. Results Immunisation with cDNA encoding the nucleocapsid protein induced strong humoral and lymphocyte proliferative immune responses, and virus neutralising antibodies were acquired after vaccination with cDNA encoding the glycoproteins. Even though complete protection was not achieved by genetic immunisation, four out of eight, and five out of eight mice vaccinated with cDNA encoding the nucleocapsid protein or the glycoproteins, respectively, displayed no clinical signs of infection after challenge. In contrast, all fourteen control animals displayed clinical manifestations of Rift Valley Fever after challenge. Conclusion The appearance of Rift Valley Fever associated clinical signs were significantly decreased among the DNA vaccinated mice and further adjustment of this strategy may result in full protection against Rift Valley Fever.